Landscapes / Targets
CLDN18.2
35 drugs act on CLDN18.2, in 75 active trials · Any stage · updated 18 Nov 2026
FollowEvery change as it happens, and a Monday email
Drugs35
| Drug | How it works | Company | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
Monoclonal antibody |
Approved | 30 Jun 2027Phase 2 trial completes | |||
| How it works | An antibody | ||||
| Next date | 30 Jun 2027 · Phase 2 trial completes | ||||
| Also tested for | Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer and 10 more | ||||
| Open drug page | |||||
— |
Phase 3 | 30 Dec 2026Phase 3 trial completes | |||
| Next date | 30 Dec 2026 · Phase 3 trial completes | ||||
| Also tested for | Gastric Cancer, Gastroesophageal Cancer (GC) and 2 more | ||||
| Open drug page | |||||
— |
Innovent · Public 1801.HK |
Phase 3 | 30 Dec 2026Phase 3 trial completes | ||
| Next date | 30 Dec 2026 · Phase 3 trial completes | ||||
| Also tested for | Locally Advanced Unresectable or Metastatic Solid Tumors, Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma and 3 more | ||||
| Open drug page | |||||
— |
Phase 2/3 | 30 Dec 2026Phase 1/2 trial completes | |||
| Next date | 30 Dec 2026 · Phase 1/2 trial completes | ||||
| Also tested for | Solid Tumor, Cervical Cancer | ||||
| Open drug page | |||||
— |
Phase 3 | Dec 2026Phase 2 trial completes | |||
| Next date | Dec 2026 · Phase 2 trial completes | ||||
| Also tested for | Advanced Solid Tumor, Gastric Adenocarcinoma and 3 more | ||||
| Open drug page | |||||
M108not checked |
— |
Phase 3 | 11 Jan 2027Phase 3 trial completes | ||
| Next date | 11 Jan 2027 · Phase 3 trial completes | ||||
| Also tested for | Locally Advanced Unresectable or Metastatic Gastric Cancer, Locally Advanced Unresectable or Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma and 3 more | ||||
| Open drug page | |||||
— |
Phase 3 | 30 Jun 2027Phase 1/2 trial completes | |||
| Next date | 30 Jun 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Advanced Cancer, Gastric Cancer and 2 more | ||||
| Open drug page | |||||
— |
Hengrui · Public 600276.SS |
Phase 3 | 20 Sep 2027Phase 3 trial completes | ||
| Next date | 20 Sep 2027 · Phase 3 trial completes | ||||
| Also tested for | Advanced Solid Cancer, Advanced Solid Tumors and 7 more | ||||
| Open drug page | |||||
Unmodified immunoglobulin |
AstraZeneca · Public AZN |
Phase 3 | 9 Nov 2027Phase 2 trial completes | ||
| How it works | An antibody | ||||
| Next date | 9 Nov 2027 · Phase 2 trial completes | ||||
| Also tested for | Gastric Cancer, Gastroesophageal Junction Cancer and 5 more | ||||
| Open drug page | |||||
— |
Phase 3 | Oct 2028Phase 3 trial completes | |||
| Next date | Oct 2028 · Phase 3 trial completes | ||||
| Also tested for | Adenocarcinoma | ||||
| Open drug page | |||||
— |
Phase 3 | 31 Jan 2029Phase 3 trial completes | |||
| Next date | 31 Jan 2029 · Phase 3 trial completes | ||||
| Also tested for | Gastric Adenocarcinoma | ||||
| Open drug page | |||||
— |
Phase 3 | Dec 2029Phase 3 trial completes | |||
| Next date | Dec 2029 · Phase 3 trial completes | ||||
| Also tested for | Locally Advanced or Metastatic Solid Tumors, Gastric Adenocarcinoma and 6 more | ||||
| Open drug page | |||||
— |
Phase 3 | 28 Feb 2031Phase 3 trial completes | |||
| Next date | 28 Feb 2031 · Phase 3 trial completes | ||||
| Also tested for | Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma and 2 more | ||||
| Open drug page | |||||
— |
Phase 3 | 6 Aug 2031Phase 2 trial completes | |||
| Next date | 6 Aug 2031 · Phase 2 trial completes | ||||
| Also tested for | Malignant Neoplasms of Digestive Organs, Locally Advanced or Metastatic GC and GCJ Adenocarcinoma | ||||
| Open drug page | |||||
— |
Phase 1/2 | 30 Dec 2026Phase 1/2 trial completes | |||
| Next date | 30 Dec 2026 · Phase 1/2 trial completes | ||||
| Also tested for | Pancreatic Adenocarcinoma Metastatic, Lung Cancer (NSCLC) and 7 more | ||||
| Open drug page | |||||
— |
Phase 1/2 | 31 Dec 2026Phase 1 trial completes | |||
| Next date | 31 Dec 2026 · Phase 1 trial completes | ||||
| Also tested for | Pancreatic Cancer, Gastric Cancer and 2 more | ||||
| Open drug page | |||||
— |
Phase 1/2 | 14 Feb 2027Phase 1/2 trial completes | |||
| Next date | 14 Feb 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Pancreatic Ductal Adenocarcinoma (PDAC), Unresectable Locally Advanced or Metastatic Disease and 2 more | ||||
| Open drug page | |||||
— |
Phase 1/2 | 14 Mar 2027Phase 1/2 trial completes | |||
| Next date | 14 Mar 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma | ||||
| Open drug page | |||||
— |
Phase 1/2 | 14 Mar 2027Phase 1/2 trial completes | |||
| Next date | 14 Mar 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Recurrent or Metastatic Esophageal Adenocarcinoma | ||||
| Open drug page | |||||
— |
AstraZeneca · Public AZN |
Phase 1/2 | 31 Mar 2027Phase 1/2 trial completes | ||
| Next date | 31 Mar 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Gastric Cancer, Gastroesophageal Junction Cancer and 2 more | ||||
| Open drug page | |||||
No drugs match “”.
About this list
- Checked
- 34 of 35 drugs. The other 1 is marked “not checked” in the list. How we check
- Matches
- The mechanism of checked drugs, and drug names, so a drug not checked yet may be missing.
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · openFDA updated 17 Nov 2026